189 related articles for article (PubMed ID: 1850692)
1. Host range determinants located on the interior of the poliovirus capsid.
Moss EG; Racaniello VR
EMBO J; 1991 May; 10(5):1067-74. PubMed ID: 1850692
[TBL] [Abstract][Full Text] [Related]
2. Allele-specific adaptation of poliovirus VP1 B-C loop variants to mutant cell receptors.
Liao S; Racaniello V
J Virol; 1997 Dec; 71(12):9770-7. PubMed ID: 9371643
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of mouse-virulent poliovirus type 1 Mahoney mutants: involvement of residues of polypeptides VP1 and VP2 located on the inner surface of the capsid protein shell.
Couderc T; Hogle J; Le Blay H; Horaud F; Blondel B
J Virol; 1993 Jul; 67(7):3808-17. PubMed ID: 8389907
[TBL] [Abstract][Full Text] [Related]
4. Mouse neurovirulence determinants of poliovirus type 1 strain LS-a map to the coding regions of capsid protein VP1 and proteinase 2Apro.
Lu HH; Yang CF; Murdin AD; Klein MH; Harber JJ; Kew OM; Wimmer E
J Virol; 1994 Nov; 68(11):7507-15. PubMed ID: 7933134
[TBL] [Abstract][Full Text] [Related]
5. Identification of two determinants that attenuate vaccine-related type 2 poliovirus.
Ren RB; Moss EG; Racaniello VR
J Virol; 1991 Mar; 65(3):1377-82. PubMed ID: 1847458
[TBL] [Abstract][Full Text] [Related]
6. Mapping of sequences required for mouse neurovirulence of poliovirus type 2 Lansing.
La Monica N; Meriam C; Racaniello VR
J Virol; 1986 Feb; 57(2):515-25. PubMed ID: 3003384
[TBL] [Abstract][Full Text] [Related]
7. Mutations in Sabin 2 strain of poliovirus and stability of attenuation phenotype.
Rezapkin GV; Fan L; Asher DM; Fibi MR; Dragunsky EM; Chumakov KM
Virology; 1999 May; 258(1):152-60. PubMed ID: 10329577
[TBL] [Abstract][Full Text] [Related]
8. Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine.
Bouchard MJ; Lam DH; Racaniello VR
J Virol; 1995 Aug; 69(8):4972-8. PubMed ID: 7609067
[TBL] [Abstract][Full Text] [Related]
9. Poliovirus variants selected on mutant receptor-expressing cells identify capsid residues that expand receptor recognition.
Colston EM; Racaniello VR
J Virol; 1995 Aug; 69(8):4823-9. PubMed ID: 7609049
[TBL] [Abstract][Full Text] [Related]
10. Cell clones cured of persistent poliovirus infection display selective permissivity to the wild-type poliovirus strain Mahoney and partial resistance to the attenuated Sabin 1 strain and Mahoney mutants.
Calvez V; Pelletier I; Couderc T; Pavio-Guédo N; Blondel B; Colbère-Garapin F
Virology; 1995 Oct; 212(2):309-22. PubMed ID: 7571400
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the poliovirus P1 capsid precursor at arginine residues VP4-ARG34, VP3-ARG223, and VP1-ARG129 affect virus assembly and encapsidation of genomic RNA.
Ansardi DC; Luo M; Morrow CD
Virology; 1994 Feb; 199(1):20-34. PubMed ID: 8116243
[TBL] [Abstract][Full Text] [Related]
12. Three-dimensional structure of a mouse-adapted type 2/type 1 poliovirus chimera.
Yeates TO; Jacobson DH; Martin A; Wychowski C; Girard M; Filman DJ; Hogle JM
EMBO J; 1991 Sep; 10(9):2331-41. PubMed ID: 1651227
[TBL] [Abstract][Full Text] [Related]
13. Mutations in VP1 of poliovirus specifically affect both encapsidation and release of viral RNA.
Kirkegaard K
J Virol; 1990 Jan; 64(1):195-206. PubMed ID: 2152812
[TBL] [Abstract][Full Text] [Related]
14. Use of type 1/type 2 chimeric polioviruses to study determinants of poliovirus type 1 neurovirulence in a mouse model.
Martin A; Benichou D; Couderc T; Hogle JM; Wychowski C; Van der Werf S; Girard M
Virology; 1991 Feb; 180(2):648-58. PubMed ID: 1846492
[TBL] [Abstract][Full Text] [Related]
15. Substitutions in the capsids of poliovirus mutants selected in human neuroblastoma cells confer on the Mahoney type 1 strain a phenotype neurovirulent in mice.
Couderc T; Guédo N; Calvez V; Pelletier I; Hogle J; Colbère-Garapin F; Blondel B
J Virol; 1994 Dec; 68(12):8386-91. PubMed ID: 7966631
[TBL] [Abstract][Full Text] [Related]
16. Nucleic acid sequence of the region of the genome encoding capsid protein VP1 of neurovirulent and attenuated type 3 polioviruses.
Stanway G; Cann AJ; Hauptmann R; Mountford RC; Clarke LD; Reeve P; Minor PD; Schild GC; Almond JW
Eur J Biochem; 1983 Oct; 135(3):529-33. PubMed ID: 6311539
[TBL] [Abstract][Full Text] [Related]
17. Structural studies of poliovirus mutants that overcome receptor defects.
Wien MW; Curry S; Filman DJ; Hogle JM
Nat Struct Biol; 1997 Aug; 4(8):666-74. PubMed ID: 9253417
[TBL] [Abstract][Full Text] [Related]
18. Reduced mouse neurovirulence of poliovirus type 2 Lansing antigenic variants selected with monoclonal antibodies.
La Monica N; Kupsky WJ; Racaniello VR
Virology; 1987 Dec; 161(2):429-37. PubMed ID: 2825415
[TBL] [Abstract][Full Text] [Related]
19. Mouse adaptation determinants of poliovirus type 1 enhance viral uncoating.
Couderc T; Delpeyroux F; Le Blay H; Blondel B
J Virol; 1996 Jan; 70(1):305-12. PubMed ID: 8523541
[TBL] [Abstract][Full Text] [Related]
20. Distribution of drug resistance mutations in type 3 poliovirus identifies three regions involved in uncoating functions.
Mosser AG; Sgro JY; Rueckert RR
J Virol; 1994 Dec; 68(12):8193-201. PubMed ID: 7966611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
